long intergenic non-protein coding RNA 1816Genealiases: []
Q-omics provides the consensus-scored LINC01816 profile across patient tissues and cancer cell-line models. LINC01816 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC01816 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LINC01816 RNA expression shows 14,482 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, KICH, and THYM as cancer lineages where LINC01816 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01816 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01816 survival associations across molecular data types. LINC01816 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01816 RNA expression–survival associations across cancer types. High LINC01816 expression shows unfavorable associations in UCEC and LUAD, but favorable associations in OV, UCS, READ and KIRP. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for LINC01816 RNA expression.
This table summarizes LINC01816 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01816. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01816 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, LUSC, LUAD and COAD. The KICH box plot shows higher LINC01816 RNA expression in normal versus tumor tissue (log2 FC = −1.667, t-test p < 0.001).
This table shows molecular features associated with LINC01816 in patient tissues and cancer cell lines. In patient samples, LINC01816 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
